Icosapent Ethyl (Vascepa), developed by Amarin, has redefined cardiovascular risk management through its highly purified EPA-only formulation and its strong clinical evidence demonstrating meaningful reductions in major adverse cardiovascular events among statin-treated patients with elevated trig...Read More »
November 24, 2025
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist used in type 2 diabetes management and for lowering cardiovascular risk in patients with underlying conditions. It supports glycemic control, weight management, and cardiovascular protection, while weekly dosing improves treatment adh...Read More »
November 20, 2025
The Europe vitamin D supplements market continues to demonstrate consistent growth, supported by aging population, increased health awareness, and a growing consumer shift towards wellness. This rise in demand reflects the broader trend of consumers proactively seeking to improve their health thro...Read More »
November 19, 2025
Elagolix (Orilissa), developed by AbbVie Inc., represents a major advancement in women’s health as the first oral gonadotropin-releasing hormone (GnRH) antagonist approved for the management of endometriosis-associated pain and uterine fibroids. Designed to provide dose-dependent estrogen su...Read More »
November 18, 2025
The enzyme indicators represent a cutting-edge advancement in sterilization monitoring, offering rapid and precise validation of sterilization processes. Enzyme indicators offer a safer, faster, and smarter method for bio-decontamination validation, enabling optimized cycle design, reducing the ri...Read More »
November 18, 2025
Relugolix Combo (Myfembree/Ryeqo), developed by Myovant Sciences now part of Sumitomo Pharma and co-commercialized with Pfizer Inc., is an oral, once-daily GnRH receptor antagonist combination indicated for uterine fibroids and endometriosis-associated pain. The therapy combines relugolix, estradi...Read More »
November 18, 2025
Breztri Aerosphere, a combination of Budesonide, Glycopyrrolate, and Formoterol Fumarate, developed and marketed by AstraZeneca, has become a prominent treatment option for chronic obstructive pulmonary disease (COPD) and asthma. The therapy’s unique triple-action mechanism incorporating a c...Read More »
November 18, 2025
Bimekizumab (Bimzelx), developed by UCB, is emerging as a highly differentiated biologic in the global immunology market through its unique dual inhibition of IL-17A and IL-17F, delivering rapid, deep, and sustained clinical responses that surpass many existing IL-17 therapies. Since securing FDA ...Read More »
November 17, 2025
Liraglutide (Victoza), developed by Novo Nordisk, is a pioneering GLP-1 receptor agonist that has reshaped the management of type 2 diabetes and obesity through its proven efficacy in glycemic control, weight reduction, and cardiovascular risk reduction. Victoza and Saxenda both contain liraglutid...Read More »
November 14, 2025
The Triptorelin (Trelstar) market is advancing as a key segment within hormone-regulating therapeutics, supported by its long-established role in prostate cancer treatment and expanding use in central precocious puberty (CPP) and assisted reproductive technologies (ART). The market continues to sh...Read More »
November 12, 2025
The Goserelin (Zoladex) market continues to evolve, supported by its established role in hormone-dependent cancers and expanding global access to generic formulations. Demand is primarily driven by its clinical utility in prostate cancer, breast cancer, and gynecologic indications, along with sust...Read More »
November 12, 2025
NielsenIQ is a global provider of retail measurement and analytics solutions, delivering comprehensive point-of-sale data, advanced analytics, and AI-enabled insights. Serving key sectors such as consumer-packaged goods, retail, beauty, and digital commerce, NielsenIQ helps manufacturers and retai...Read More »
November 11, 2025
The U.S. independent pharmacies market size was valued at USD 172.56 billion in 2024 and is expected to expand at a CAGR of 4.26% from 2025 to 2033. The study covers more than 11,000 independent pharmacies at state level which helps to understand details regarding their location, address, ownershi...Read More »
November 11, 2025
The cell culture industry is undergoing a competitive reshaping driven by the advance of cell and gene therapies, deeper adoption of chemically defined specialty formulations, and increasing emphasis on regulatory-grade traceability. While traditional cell lines and classical media remain foundati...Read More »
November 11, 2025
Givosiran (Givlaari) is a first-in-class RNA interference (RNAi) therapy developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP). The drug offers disease-modifying benefits by reducing aminolevulinic acid (ALA) and porphobilinogen (PBG) levels, resulting in a marked...Read More »
November 11, 2025
The Europe dietary supplements market continues to demonstrate consistent growth, supported by aging populations, increased preventive health awareness, and a widening consumer shift toward wellness-driven lifestyles. Supplement purchases have diversified across retail ecosystems pharmacies and dr...Read More »
November 11, 2025
Selpercatinib, marketed under the brand name Retemo, represents a significant advancement in the treatment of RET-driven cancers, including non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Approved by the FDA in 2020, Retemo is the first selective RET kinase inhibitor approve...Read More »
November 10, 2025
Sofosbuvir + Velpatasvir (Epclusa), developed by Gilead Sciences, represents a transformative milestone in hepatitis C virus (HCV) treatment as the first once-daily, pan-genotypic direct-acting antiviral (DAA) combination. By uniting a nucleotide analog polymerase inhibitor (sofosbuvir) with an NS...Read More »
November 10, 2025
Baloxavir marboxil (Xofluza), developed by Shionogi & Co., Ltd. and co-commercialized with Roche (Genentech), represents a major advancement in influenza antiviral therapy. Approved by the U.S. FDA in 2018, Xofluza introduced the first single-dose, oral treatment for acute uncomplicated influe...Read More »
November 10, 2025
Brolucizumab (Beovu) Market represents a key segment within the retinal disease treatment landscape, primarily addressing neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). Developed by Novartis, Beovu is a humanized single-chain antibody fragment (scFv) ta...Read More »
November 10, 2025